Daewoong's stake was diluted by the July 2026 offering and subsequent warrant exercises, but it remains the largest holder at ~30.6%. The upcoming December 15, 2026 special meeting on a reverse stock split and plan amendments could affect the stock's liquidity and Daewoong's future conversion/exercise decisions.
AEON drugs
AEON drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $0.1793entry
- T+1 · 6d ago −4.41%α −5.72% · $0.1714
- T+4 · todayOpen
- T+5 · in 6h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Daewoong Co., Ltd. and its affiliate Daewoong Pharmaceutical Co., Ltd. filed an amendment to their Schedule 13D for AEON Biopharma, reporting the cashless exercise of pre-funded warrants on October 30, 2026, which added 11,232,809 shares to their holdings. Their combined beneficial ownership rose from 12,009,737 shares to 23,242,546 shares, but their percentage stake decreased from 49.99% to approximately 30.6% due to substantial dilution from the company's July 2026 public offering and subsequent warrant exercises by other holders. The filing reflects a routine warrant conversion with no change in purpose or demands.
Key Financial Metrics
Key Facts
- Daewoong Pharmaceutical exercised pre-funded warrants on a cashless basis on October 30, 2026, receiving 11,232,809 shares of Class A Common Stock.
- Combined beneficial ownership increased from 12,009,737 shares to 23,242,546 shares.
- Ownership percentage decreased from 49.99% to approximately 30.6% due to dilution from the July 2026 offering and subsequent warrant exercises by other holders.
- The company's outstanding share count rose from 26,307,211 (July 10, 2026) to 76,009,476 (November 9, 2026).
- Daewoong still holds a warrant for 8,000,000 shares at $1.09392 per share and a Senior Secured Convertible Note, neither of which is exercisable within 60 days.
- No change in stated purpose or demands; the filing is a routine update to report the warrant exercise and dilution.
Financial Impact
No cash involved; 11,232,809 shares issued via cashless exercise. Daewoong's percentage stake diluted from 49.99% to 30.6% due to the company's capital raises.
Risk Factors
- Further dilution from outstanding warrants (8,000,000 shares) and convertible note held by Daewoong.
- Low market cap ($12M) and high volatility (9.2% normal daily move) increase stock price sensitivity to any corporate actions.
- Potential for additional equity raises given the company's cash needs as a pre-revenue biopharma.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001213900-26-117881 |
| Document: 0001213900-26-117881-index.html | 0001213900-26-117881 |
| Document: 0001213900-26-117881.txt | 0001213900-26-117881 |
Track record
22 reports on AEON
8 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +44.50% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.1600 Now $0.1410 −11.87% settles Nov 24
- Nov 16, 2026today Press Release Neutral 5/10 Entry $0.1410 Now $0.1410 +0.00% settles Nov 24
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $0.1610 Now $0.1410 −12.42% settles Nov 23
- Nov 10, 20266d ago SC 13D/A Neutral 3/10 Viewing Entry $0.1793 Now $0.1410 −21.36% settles Nov 17
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1818 to $0.1407 Now $0.1410 −22.44% ▼ −22.61% −20.91% vs SPY
- Nov 3, 202613d ago 8-K Neutral 4/10 Entry $0.2122 to $0.1793 Now $0.1410 −33.55% ▼ −15.50% −14.92% vs SPY
- Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $0.2483 to $0.2122 Now $0.1410 −43.21% ▼ −14.54% −12.55% vs SPY
- Oct 23, 202624d ago 8-K Neutral 4/10 Entry $0.2400 to $0.2740 Now $0.1410 −41.25% ▲ +14.17% +15.43% vs SPY
- Sep 30, 20266w ago 8-K Bullish 7/10 Entry $0.3000 to $0.3110 Now $0.1410 −53.00% ▲ +3.67% +1.75% vs SPY
- Aug 21, 202612w ago 3 Neutral Not scored Entry $0.1974 to $0.2959 Now $0.1410 −28.57% ▲ +49.90% +49.43% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers